Julia Ernst, MS

Decreased levels of plasma amyloid beta 42 at midlife, but not late life, correlated with an increased risk for dementia and a “marginally higher” risk for mild cognitive impairment, according to findings published in Neurology.

Direct transfer to an angiography suite within 6 hours of stroke onset increased rates of endovascular therapy, reduced hospital workflow time and enhanced clinical outcomes, according to findings published in JAMA Neurology.

Metabolic syndrome demonstrated significant correlations with both stroke recurrence and all-cause mortality, according to the results of a meta-analysis of 13 cohort studies with nearly 60,000 participants published in Neurology.

Results from an analytical decision model demonstrated that short-term, 7-day prophylaxis “dominates” long-term therapy for seizure prophylaxis after spontaneous intracerebral hemorrhage.

The online tool Outreach Pro was launched at the Alzheimer’s Association International Conference to raise awareness of clinical trials for Alzheimer’s disease and other dementias, specifically in “traditionally underrepresented communities.”

Forgetfulness continued in more than half of older adults studied between 3 to 6 months after COVID-19, while one in four experienced added issues with cognition, including language and executive dysfunction.

Adrenocorticotropic hormone and oral steroids demonstrated superiority compared with non-standard therapy for the initial treatment of infantile spams in a prospective, multicenter observational cohort study published in Neurology.

Projections presented at the Alzheimer’s Association International Conference estimate that dementia cases will almost triple to more than 152 million by 2050, with the greatest increases expected in Africa and the Middle East.

Aduhelm demonstrated a consistent treatment effect for slowing decline in cognitive, functional and behavioral domains among patients with early Alzheimer’s disease in item-level analysis of the phase 3 EMERGE study.

Individuals with late-onset epilepsy experienced an increased risk for death compared with individuals without epilepsy, even after adjustment for comorbidities, according to findings published in Neurology.